PHAT Earnings Date: Feb 25, 2027 (Estimated) — Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PHAT's next earnings date?
Phathom Pharmaceuticals, Inc. (PHAT) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.10 on revenue of $98.4M.
How did PHAT do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Phathom Pharmaceuticals, Inc. posted EPS of $0.04 versus the -$0.11 estimate, a beat of 136.5%. Revenue was $84.7M against a $84.8M estimate. The stock's 1-day post-earnings move was -1.0%.
How much does PHAT stock move after earnings?
PHAT beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.5% (up or down) in the day after earnings.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
🤖 AI Earnings Analysis
VOQUEZNA’s launch is gaining traction, surpassing 2 million prescriptions through October; Q3 revenue rose 71% year over year to $84.7 million. The $0.04 EPS beat is encouraging, but operating losses persist.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.11 | 0.04 | +136.46% | $84.7M | ✅ Beat | -0.96% | — | — |
| 2026-07-30 | Q2 2026 | -0.11 | 0.00 | +100.00% | $74.3M | ✅ Beat | -22.42% | -29.30% | -23.20% |
| 2026-04-30 | Q1 2026 | -0.21 | -0.18 | +14.29% | $58.3M | ✅ Beat | -4.92% | +7.56% | -18.59% |
| 2026-02-26 | Q4 2025 | -0.19 | -0.08 | +57.89% | $57.6M | ✅ Beat | +10.06% | -10.23% | -12.42% |
| 2025-10-30 | Q3 2025 | -0.41 | -0.15 | +63.41% | $49.5M | ✅ Beat | -1.63% | -1.85% | +15.45% |
| 2025-03-06 | Q4 2024 | -1.08 | -0.79 | +26.85% | $29.7M | ✅ Beat | -2.96% | -17.76% | -17.68% |
| 2024-11-07 | Q3 2024 | -1.49 | -1.05 | +29.53% | $16.4M | ✅ Beat | +2.78% | -45.83% | -50.00% |
| 2024-03-07 | Q4 2023 | -1.08 | -1.39 | -28.70% | $682,000 | ❌ Miss | -6.58% | -17.78% | +13.36% |
Showing last 8 quarters.